Back to funds
View filing
Foresite Capital Management IV, LLC
hedge fundUpdated 27 days agoManaged by Foresite Capital Management Iv, Llc • Latest filing Q2 2026
Portfolio value
$290.2M
Q2 2026
Filings
14
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
6.6%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 14 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $192.7M |
| Q2 2023 | $203.4M |
| Q3 2023 | $180M |
| Q4 2023 | $197.9M |
| Q1 2024 | $197.9M |
| Q2 2024 | $148.8M |
| Q3 2024 | $153M |
| Q4 2024 | $108.8M |
| Q1 2025 | $111.1M |
| Q2 2025 | $123.8M |
| Q3 2025 | $182.6M |
| Q4 2025 | $229.7M |
| Q1 2026 | $237.1M |
| Q2 2026 | $290.2M |
Top holdings
6 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | P PHVS Pharvaris N.V. | $165.2M | 4.78M | 56.95% | — |
| 2 | C CYTK CYTOKINETICS INC | $60.9M | 714.7K | 20.98% | — |
| 3 | E EIKN Eikon Therapeutics, Inc. | $25.4M | 1.94M | 8.74% | — |
| 4 | R RLAY Relay Therapeutics, Inc. | $23.4M | 1.25M | 8.06% | — |
| 5 | X XENE Xenon Pharmaceuticals Inc. | $9.7M | 160.0K | 3.33% | — |
| 6 | C CRNX Crinetics Pharmaceuticals, Inc. | $5.6M | 150.0K | 1.93% | — |